Insmed (INSM) Competitors

Insmed (NASDAQ:INSM) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.

Do institutionals & insiders believe in INSM or TAK?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 3.0% of Insmed shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, INSM or TAK?

Insmed has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Do analysts rate INSM or TAK?

Insmed presently has a consensus target price of $94.00, indicating a potential upside of 29.41%. Given Insmed's higher probable upside, research analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	0 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer INSM or TAK?

In the previous week, Insmed had 16 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 25 mentions for Insmed and 9 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 1.16 beat Takeda Pharmaceutical's score of 1.14 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	17 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, INSM or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$363.71M	36.31	-$749.57M	-$5.59	-12.99
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.40	37.56

Is INSM or TAK more profitable?

Takeda Pharmaceutical has a net margin of 4.53% compared to Insmed's net margin of -251.24%. Takeda Pharmaceutical's return on equity of 9.39% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-251.24%	-4,773.73%	-54.58%
Takeda Pharmaceutical	4.53%	9.39%	4.53%

Does the MarketBeat Community prefer INSM or TAK?

Insmed received 456 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 66.87% of users gave Insmed an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Insmed	Outperform Votes 557 66.87%	Underperform Votes 276 33.13%
Takeda Pharmaceutical	Outperform Votes 101 57.06%	Underperform Votes 76 42.94%

Summary

Insmed beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.